WO1999053977A1 - System for stress relieving the heart muscle and for controlling heart function - Google Patents

System for stress relieving the heart muscle and for controlling heart function Download PDF

Info

Publication number
WO1999053977A1
WO1999053977A1 PCT/US1999/008713 US9908713W WO9953977A1 WO 1999053977 A1 WO1999053977 A1 WO 1999053977A1 US 9908713 W US9908713 W US 9908713W WO 9953977 A1 WO9953977 A1 WO 9953977A1
Authority
WO
WIPO (PCT)
Prior art keywords
heart
strips
protrusions
wall
elongation
Prior art date
Application number
PCT/US1999/008713
Other languages
French (fr)
Inventor
Dnyanesh Talpade
Original Assignee
Scimed Life Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems, Inc. filed Critical Scimed Life Systems, Inc.
Priority to JP2000544377A priority Critical patent/JP4190730B6/en
Priority to EP99917645A priority patent/EP1073488A1/en
Priority to CA002329735A priority patent/CA2329735A1/en
Publication of WO1999053977A1 publication Critical patent/WO1999053977A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2478Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
    • A61F2/2481Devices outside the heart wall, e.g. bags, strips or bands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/10Location thereof with respect to the patient's body
    • A61M60/122Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body
    • A61M60/165Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable in, on, or around the heart
    • A61M60/191Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient's body implantable in, on, or around the heart mechanically acting upon the outside of the patient's native heart, e.g. compressive structures placed around the heart
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/20Type thereof
    • A61M60/289Devices for mechanical circulatory actuation assisting the residual heart function by means mechanically acting upon the patient's native heart or blood vessel structure, e.g. direct cardiac compression [DCC] devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/50Details relating to control
    • A61M60/508Electronic control means, e.g. for feedback regulation
    • A61M60/515Regulation using real-time patient data
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/50Details relating to control
    • A61M60/508Electronic control means, e.g. for feedback regulation
    • A61M60/538Regulation using real-time blood pump operational parameter data, e.g. motor current
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/33Controlling, regulating or measuring
    • A61M2205/3303Using a biosensor

Definitions

  • the present invention deals with treatment of heart disease. More particularly, the present invention deals with a system and method for treating heart disease by regulating blood flow in the vasculature.
  • Congestive heart failure is a common heart disease.
  • the prevalence of incidents of congestive heart failure has recently increased, and there is considerable morbidity and mortality associated with its diagnosis.
  • congestive heart failure is an extremely lethal disease with an estimated five year mortality for a vast majority of both men and women who encounter the disease.
  • Congestive heart failure results from loss of, or impairment of, normal heart function. This loss or impairment reduces cardiac output. This, in turn, results in a reduction in both blood flow and blood pressure in the kidneys. This reduction in flow and pressure causes a renin-angiotensin response that exacerbates congestive heart failure.
  • renin cleaves a ten-amino acid polypeptide called angiotensin I from a plasma protein in the blood called angiotensinogen.
  • a converting enzyme in the blood removes two amino acids from the angiotensin I polypeptide leaving an eight amino acid polypeptide called angiotensin II.
  • Angiotensin II has numerous effects on the smooth muscle layers of arterioles, including causing vasoconstriction. Further, an indirect effect of an increase in angiotensin II increases blood volume.
  • Blood volume is increased because angiotensin II stimulates secretion of aldosterone from the adrenal cortex which, in turn, causes an increase in salt and water retention in the kidneys. Angiotensin II also stimulates thirst centers in the hypothalamus causing more water to be ingested.
  • the increase in blood volume and the corresponding vasoconstriction cause an increase in blood pressure and hence a volume overload on the heart which causes further deterioration of the heart condition.
  • Baroreceptors referred to as stretch receptors, reside in the aortic arch and carotid sinuses.
  • the baroreceptors are essentially pressure sensors sensing blood pressure in that area.
  • the baroreceptors provide physiological feedback in two ways. First, in response to a reduction in blood pressure, the baroreceptors provide a neurohormonal feedback response which acts to increase the heart rate in an attempt to increase cardiac output .
  • the increased heart rate causes the heart to work harder which, in turn, causes the heart muscle to stretch further.
  • a reduction in pressure caused by a reduction in cardiac output causes the baroreceptors to provide a feedback response which acts to constrict the distal vasculature thus increasing pressure in that area.
  • a cyclical feedback response which increases, rather than reduces, the impairment.
  • Such a cyclical feedback response is sometimes referred to as a cascade .
  • Muscles are thought of as being composed of many fibers which contract and lengthen to accomplish muscular action. Each fiber includes many densely packed subunits referred to as myofibrils which are on the order of 1 ⁇ m in diameter and extend in parallel from one end of the muscle fiber to the other. Each myofibril has spaced regions of thick filaments (about 110A thick) and thin filaments (about 50-60A thick) .
  • the thick filaments are formed of a protein, myosin, and the thin filaments are formed of a protein, actin.
  • the actin and myosin filaments overlap in regions periodically spaced along the myofibrils.
  • the units in the repeated overlapping pattern are referred to as sarcomeres .
  • Contraction of a muscle fiber results from shortening of the myofibrils which form the muscle fiber.
  • the myofibrils are shortened, but the individual filaments in the myofibrils do not decrease in length. Instead, the actin and myosin filaments slide longitudinally relative to one another to shorten the overall length of the myofibrils. Sliding occurs as a result of cross-bridges extending from the myosin toward the actin attaching to the actin at bonding sites.
  • the cross bridges are oriented to draw overlapping actin filaments on either longitudinal side of the myosin filament toward the longitudinal center of the myosin filament.
  • This inefficient or impaired heart function causes blood pressure in the areas of both the kidneys and the baroreceptors to decrease.
  • the feedback response generated by the kidneys causes further overload and stress on the heart .
  • the feedback response generated by the baroreceptors causes increased heart rate . Both of these feedback responses cause the heart to work harder, causing further stretching of the heart muscle and thus leading to greater inefficiencies. In response, the feedback responses become even more acute -- and the cascade continues.
  • This cascade effect which is a natural progression of congestive heart failure, leads to increased muscle mass and stretching of the heart muscle fibers which, in turn, leads to muscular hypertrophy of the left ventricle.
  • the hypertrophy is a compensatory mechanism which, if maintained at a given level such that muscle fibers maintain inherent contractile properties (i.e., actin-myosin overlap), can be beneficial for maintaining proper heart function.
  • prolonged and continuous stretching causes muscular fatigue and reduced muscle performance as explained by the known Frank-Starling mechanism.
  • An apparatus and method restrict elongation of heart muscle tissue in a wall of a heart having a chamber.
  • a plurality of biocompatible and implantable elongate strips are configured to be connected to the heart wall and disposed about the chamber such that the elongate strips are arranged in spaced relation to one another.
  • the elongate strips are bendable and are sufficiently resistant to elongation such that natural - 5 - stretching of the heart wall does not cause elongation of the plurality of strips.
  • FIG. 1A is a side sectional view of a heart.
  • FIG. IB is a greatly enlarged sectional view of a portion of the heart shown in FIG. 1A.
  • FIG. 2 illustrates a retention strip in accordance with one aspect of the present invention.
  • FIG. 3 illustrates the retention strip shown in FIG. 2 embedded in the heart wall.
  • FIG. 4 illustrates a plurality of the strips as shown in FIG. 2 embedded in the wall of the left ventricle .
  • FIG. 5 illustrates a second embodiment of a retention mechanism in accordance with one aspect of the present invention.
  • FIG. 6A shows the retention mechanism illustrated in FIG. 5 deployed on the outer surface of the left ventricle.
  • FIG. 6B is a sectional view of a portion of the heart wall shown in FIG. 6A.
  • FIG. 7 illustrates another embodiment of a monitoring system in accordance with one aspect of the present invention.
  • FIG. 8 illustrates a portion of the monitoring system shown in FIG. 7 in schematic and partial block diagram form.
  • FIG. 9 illustrates another embodiment of a monitoring and control system in schematic and partial block diagram form.
  • FIG. 1A illustrates a portion of a heart 10.
  • FIG. 1A illustrates a plurality of chambers in heart 10 including right ventricle 12 and left ventricle 14.
  • FIG. 1A also illustrates heart wall 16 which extends around chambers 12 and 14, and separates chambers 12 and 14.
  • congestive heart failure can lead to hypertrophy of the muscle fibers in heart 10, particularly those surrounding left ventricle 14.
  • FIG. IB illustrates a greatly enlarged sectional view of a portion of wall 16 of heart 10 shown in FIG. 1A.
  • FIG. IB is taken from the portion labeled IB in FIG. 1A.
  • FIG. IB illustrates that wall 16 is formed of an endocardium layer 18 which comprises the inner tissue of heart wall 16.
  • Heart wall 16 also includes an epicardium layer 20 which comprises the outer tissue in heart wall 16.
  • Mid-wall portion 22 comprises a portion of wall 16 between the endocardium 18 and epicardium 20.
  • the pericardium is a double- walled sac which encloses the heart.
  • the inner layer of the pericardial sac comprises the epicardium 20.
  • Photomicrographs available from the American Heart Association libraries show that the alignment of cardiac muscle fibers are generally perpendicular to the ventricular cavity wall in the endocardium 18 and epicardium 20. Also, the muscle fibers are typically nearly parallel to the ventricular cavity wall in the mid-wall portion 22. During hypertrophy of the muscular wall 16 around the left ventricle 14, the muscle fibers stretch and elongate in a direction generally parallel to their longitudinal orientation. Thus, the muscle fibers in the endocardium 18 and epicardium 20 elongate in a direction generally perpendicular to the ventricular cavity wall. Also, the muscle fibers in the mid-wall region 22 elongate in a direction generally parallel to the ventricular cavity wall. Additional muscle fibers also develop. All of these effects contribute to an increase in muscle mass and stretching of the heart muscle fibers.
  • FIG. 2 illustrates a retention strip 24 in accordance with one aspect of the present invention.
  • Retention strip 24 in one preferred embodiment, includes a generally longitudinal strut 26 with a first set of protrusions 28, 30 and 32 extending from strut 26 in a first direction and a second plurality of protrusions 34 and 36 extending from longitudinal strut 26 in a second direction, generally opposite the first direction. While protrusions 28, 30 and 32 are shown to have a generally T-shaped conformation, and while protrusions 34 and 36 have a generally linear conformation, it should be noted that all of struts 28- 36 could either have a T conformation or a linear conformation .
  • Retention strip 24 is also shown having a plurality of apertures 38 which are used for suturing retention strip 24 in place.
  • the number and placement of the suture apertures 38 shown in FIG. 2 is illustrative only. More or less apertures 38, and apertures having different placement on retention strip 24 are contemplated as well.
  • Strut 26 and protrusions 28-36 are preferably formed of a material which allows repeated bending cycles, without permanent deformation or breakage. However, strut 26 and protrusions 28-36 are also preferably formed of a material which exhibits high resistance to elongation in the longitudinal direction. Suitable materials include collagen, or biocompatable and implantable polymer strips, as well as - 8 - biocompatable and implantable metals, cartilage, or composite materials, Nitinol and bovine and porcine byproducts, as examples.
  • FIG. 3 illustrates a portion of wall 16 with retention strip 24 implanted therein.
  • longitudinal strut 26 is implanted in the mid-wall region 22 of wall 16.
  • Protrusions 28, 30 and 32 extend into the endocardium layer 18, while protrusions 34 and 36 (and any other suitable number of protrusions) extend into the epicardium layer 20.
  • Retention strip 24 is then sutured in place by an appropriate suturing technique using apertures 38 in retention strip 24.
  • Retention strip 24 preferably extends throughout substantially the entire longitudinal length of the ventricular cavity wall, such as from the base to the apex of the ventricular cavity wall .
  • FIG. 4 illustrates a plurality of retention strips 24 embedded in wall 16 about left ventricle 14.
  • Retention strips 24 are preferably arranged at regular intervals about left ventricle 14 to encircle left ventricle 14 in wall 16. Such placement forms a restrictive cage around left ventricle 14 of heart 10. Strips 24 thus provide very little, or no impedance to the natural contractile motion of the heart. However, fixturing of retention strips 24 to the tissue of the heart with sutures prevents enlargement or substantially eliminates enlargement and extensive stretch of the muscle fibers . Since longitudinal strut 26 is substantially resistant to elongation in its longitudinal direction, it helps to prevent elongation of the muscle fibers in mid-wall region 22.
  • protrusions 28, 30 and 32 are highly resistant to elongation in their longitudinal directions, they greatly inhibit elongation or stretch of the muscle fibers in endocardium layer 18.
  • protrusions 34 and 36 are highly resistant to elongation in their longitudinal direction, they greatly inhibit elongation or stretch of the muscle fibers in endocardium layer 20.
  • Placement of retention strips 24 in the positions illustrated in FIG. 4 thus restrict the progression of congestive heart failure of the muscle due to the pressure overload on left ventricle 14.
  • the muscle is supported in such a way that it is not allowed to progressively increase its mass, and also such that uncontrolled stretching is limited by physically restricting its growth and stretch. Thus, heart failure can be controlled.
  • the recruitable muscle mass can still perform a satisfactory job due to the limited constraint on its contraction, no additional or compensatory muscle mass is generated, which also restricts growth of new muscle tissue in wall 16.
  • This aspect of the present invention thus reduces fatigue of the heart muscle and allows for natural regeneration of healthy cardiac tissue.
  • supporting the cardiac muscle tissue relives tension on the chordae tendinae which, in turn, helps prevent mitral valve regurgitation which prevents higher mean atrial pressures and thus pulmonary edema.
  • FIG. 5 illustrates another embodiment of a retention device 40 in accordance with another aspect of the present invention.
  • heart 10 may already have started to hypertrophy and thus may be vulnerable to trauma. Thus, extensive incision in heart 10 may be undesirable.
  • retention device 40 can be used by attaching it to the epicardial surface of heart 10 with only - 10 - minimal intrusion into the heart muscle (such as with sutures, adhesives, staples, or other connection techniques) .
  • Retention device 40 includes a first generally circular strap 42 and a second generally circular strap 44. Straps 42 and 44 are connected to one another by a plurality of generally longitudinal straps 46, 48, 50, 52 and 54. Straps 46-54 are preferably attached to circular strips 42 and 44 by a suitable adhesive, by welding, or by another suitable mechanism, or are formed integrally with circular straps 42. Straps 42-54 are preferably formed of collagen, polymer or metal fibers which exhibit the capability of undergoing many bending cycles, without permanent deformation of damage. Straps 42-54 are also formed to exhibit high resistance to elongation in the generally longitudinal directions.
  • straps 42-54 have a plurality of apertures 56 therein which are used to attach retention device 40 to the heart wall 16 with an appropriate suturing technique.
  • any suitable number of straps 42-54 can be used.
  • the arrangement of straps 42-54 can also be changed as desired.
  • the number and placement of suture apertures 56 can be changed to any suitable number and location on straps 42-54.
  • FIG. 6A illustrates retention device 40 deployed on wall 16 of left ventricle 14.
  • FIG. 6A illustrates that, in one preferred embodiment, straps 42-54 are periodically, and alternately, sutured to the outer surface of epicardium 20, and embedded within wall
  • FIG. 6A also illustrates that more longitudinal straps can be used than are illustrated in FIG. 5. This simply illustrates that any desired number of longitudinal straps can be used. In the preferred - 11 - embodi ent, in the areas where straps 42-54 are embedded in wall 16, they are embedded only in the epicardium layer 20 such that extensive incisions into wall 16 need not be made .
  • FIG. 6B better illustrates embedding of straps
  • FIG. 6B is a greatly enlarged cross-section of wall 16 taken in the region labeled 6B in FIG. 6A.
  • FIG. 6B illustrates that strap 46, at alternate portions 58 is simply sutured to the exterior of epicardium layer 20, while at other portions 60 is embedded within the epicardium layer 20.
  • straps 42-54 could be embedded more deeply in the wall 16. However, embedding in epicardial layer 20 is preferred.
  • retention device 40 restricts the progression of failure of heart muscle 16 due to pressure overload on the left ventricle 14 of heart 10.
  • Heart 10 is not allowed to progressively increase its mass and since the uncontrolled stretching of the heart muscle is physically restricted, heart failure can be controlled. Further, since the recruitable muscle mass is still capable of operating satisfactorily, no additional, compensatory muscle mass needs to be generated. Retention device 40 thus restricts growth of new muscle. Further, retention device 40 allows for minimal internal damage to heart 10.
  • FIG. 7 illustrates another embodiment of retention device 40 in accordance with one aspect of the present invention.
  • Retention device 40 shown in FIG. 7, is similar to that shown in FIG. 5, and similar items are similarly numbered.
  • the longitudinal straps 46-54 (only four of which are shown in FIG. 7) are each provided with a plurality of sensors 62 which - 12 - are configured to sense stretching, and/or other physiologic parameters, such as electrical activity, acceleration or physicochemical activity, of the cardiac muscle wall 16.
  • sensors 62 are only provided on longitudinal strap 48, it will be appreciated that, in a preferred embodiment, sensors 62 are similarly disposed on each of the straps 42-54.
  • Sensors 62 are preferably wire bond strain gauges, piezopolymer strips, or other strain measuring sensors. As is generally known, some such strain gauges are provided with a resistive bridge having a signal, such as a voltage, applied thereacross . As strain on the bridge changes, the values of signals received from the bridge change in a differential manner. In piezopolymer elements, application of a mechanical stress to the device generates electric polarization which can also be sensed. Thus, each sensor 62 provides one or more conductors 64 which carry signals indicative of the stretching of muscle wall 16. Such conductors are preferably provided through a suitable cable 66 to monitor circuit 68 which, in turn, is coupled to a user input/output (I/O) device 70.
  • I/O user input/output
  • the strain information captured by the signals conducted by conductors 64 to monitor circuit 68 is processed to obtain a total stretch response in the myocardium of heart 10. Such processing preferably occurs in monitor circuit 68 and is described below.
  • the total stretch response is preferably monitored for variations and thus provides information about the stretching and condition of heart 10. This information is preferably used for the treatment and management of the heart failure condition, either by itself through observation, or used to generate a feedback signal which can be used to pace - 13 - heart 10 for maximal contraction (which is described in greater detail with respect to FIG. 9) .
  • User I/O device 70 is preferably any suitable I/O device, such as a cathode ray tube, an LCD display, a strip or other printer, or any other suitable I/O device. I/O device 70 may also allow user input functions by including a keypad, a keyboard, or other user actuable elements.
  • FIG. 8 illustrates a more detailed block diagram of one embodiment of monitor circuit 68.
  • Monitor circuit 68 preferably includes a plurality of differential amplifiers 72, 74 and 76, a circuit (such as a summing amplifier, multiplexer, etc.) 78 and a microprocessor or microcontroller based circuit 80.
  • monitor circuit 68 may also include other signal filtering and amplification, and other general signal conditioning circuitry, which is generally known for conditioning signals from strain sensors and is not described here in detail.
  • differential amplifiers 72-76 are provided for amplifying the signals received from strain sensors 62.
  • each strain sensor 62 has a corresponding differential amplifier.
  • multiplexing circuity can be used to switch the signals from sensors 62 into a single, or into one or more of the differential amplifiers.
  • the output signals from differential amplifiers 72-76 are provided to circuit 78.
  • circuit 78 is a summing amplifier, the signals are summed in a desired manner to obtain the total stretch response of the myocardium of heart 10.
  • the signal from amplifier 78 is provided to microprocessor 80 where it is preferably corrected for any non-linearities and - 14 - temperature affects, in a known manner.
  • Microprocessor 80 then generates a suitable output signal to user I/O device 70.
  • circuit 78 In another embodiment in which circuit 78 is a multiplexer, each of the signals from amplifiers 72-76 are switched into microprocessor 80 under the control of microprocessor 80. Alternatively, circuit 78 can also be eliminated. In that embodiment, the outputs from amplifiers 72-76 are provided as discrete inputs to microprocessor 80. It should also be noted that other inputs can be provided to microprocessor 80 as well, such as EKG information, blood pressure information, or other sources of information. In any case, microprocessor 80 generates a signal to user I/O device 70 based on the signals from amplifiers 72-76.
  • FIG. 9 illustrates another embodiment of a monitoring and control system 82 in accordance with one aspect of the present invention.
  • system 82 each sensor 62 is provided with a strain sensing element 84, as discussed above, and an excitation electrode 86.
  • Excitation electrodes 86 are preferably conventional pacing electrodes capable of delivering pacing voltages to the myocardium of heart 10. While the sensing elements 84 and pacing electrodes 86 are shown attached to one another in FIG. 9, it should be noted that they can be separated from one another, but are preferably closely proximate one another when deployed on one of straps 42- 54.
  • microprocessor 80 receives the stretch response information from sensor elements 84 which indicates not only long term stretching of the heart muscle fibers, but which also - 15 - indicates contractile motion of the heart 10 in a pulsatile fashion. Based upon this information, microprocessor 80 generates a plurality of feedback signals which are provided to each of pacing electrodes 86. The feedback signals are used to energize pacing electrodes 86 to deliver the necessary pacing voltages to the myocardium of heart 10 in order to pace heart 10. In one preferred embodiment, microprocessor 80 simply energizes all of electrodes 86 at one time to cause contraction of the heart muscle.
  • the microprocessor 80 selectively and sequentially energizes each of the excitation electrodes 86 in order to sequentially pace different sets of electrodes 86 to achieve optimal contraction of the ventricles.
  • the output of each of differential amplifiers 72, 74 and 76 can be individually provided to microprocessor 80, as well as through, for example, a summing amplifier 78.
  • Microprocessor 80 in a preferred embodiment, also calculates and delivers appropriate pacing voltages to the various sets of excitation electrodes 86 being controlled.
  • system 82 when used in conjunction with retention device 40 restricts the progression of failure of the muscle of heart 10 due to the pressure overload in the left ventricle 14.
  • the muscle in heart 10 is preferably supported such that it is not allowed to progressively increase its mass, and so as to restrict uncontrolled stretch of the heart muscle in order to control heart failure. Since the muscle is not allowed to reach a point of destructive stretching, the muscle fibers maintain their inherent contractile properties
  • the present invention is used to deliver a drug or other therapeutic agent to the tissue with which it is used.
  • the struts, protrusions, retention strips, etc. are coated or impregnated with or otherwise provided with the therapeutic agent which is preferably engineered to be released into the adjacent tissue over time.
  • drugs or therapeutic agents illustratively include genetic therapeutic agents like growth factors, angiogenics, angiotensin converting enzymes, or contractibility promoters (such as that sold under the name Digitalis) or other suitable drugs.
  • the heart muscle can benefit from suturing or other manipulations of the heart muscle in accordance with the present invention. This benefit results from myocardial revascularization which is a known angiogenic effect which regenerates cardiac tissue.
  • the present invention reduces fatigue of the heart and allows for natural regeneration of healthy cardiac tissue, or increases the efficiency of pharmacologically administered treatments. It is also believed that supporting the cardiac muscle in this way relieves tension on the chordae tendinae which in turn prevents mitral valve regurgitation thus preventing higher mean atrial pressures and pulmonary edema. All of these factors contribute to the cascade of failures in organs and systems associated with congestive heart failure. Once the relaxed heart muscle has regained - 17 - many of its own contractile properties, it can be weaned from the pacing routine.
  • the present invention contemplates implementing the techniques and devices described herein not only on the left ventricle, but also on the right ventricle or the other chambers of the heart. Further, the present invention can be implemented on any desired combination of chambers.

Abstract

An apparatus and method for relieving stress on a heart muscle tissue in a wall (16) of a heart (10) having a chamber (14). A plurality of biocompatible and implantable elongate strips (24, 42-54) are configured to be connected to the heart wall (16) and disposed about the chamber (14) such that the elongate strips (24, 42-54) are arranged in spaced relation to one another. The elongate strips (24, 42-54) are bendable and are sufficiently resistant to elongation such that natural stretching of the heart wall (16) does not cause elongation of the plurality of strips (24, 42-54).

Description

- 1 -
SYSTE FOR STRESS RELIEVING THE HEART MUSCLE AND FOR CONTROLLING HEART FUNCTION
BACKGROUND OF THE INVENTION The present invention deals with treatment of heart disease. More particularly, the present invention deals with a system and method for treating heart disease by regulating blood flow in the vasculature.
Congestive heart failure is a common heart disease. The prevalence of incidents of congestive heart failure has recently increased, and there is considerable morbidity and mortality associated with its diagnosis. In fact, congestive heart failure is an extremely lethal disease with an estimated five year mortality for a vast majority of both men and women who encounter the disease.
Congestive heart failure results from loss of, or impairment of, normal heart function. This loss or impairment reduces cardiac output. This, in turn, results in a reduction in both blood flow and blood pressure in the kidneys. This reduction in flow and pressure causes a renin-angiotensin response that exacerbates congestive heart failure.
Briefly, as blood flow and pressure is reduced in the kidneys, cells in the kidneys referred to as juxtaglomerular apparatus secret an enzyme referred to as renin into the blood. The enzyme renin cleaves a ten-amino acid polypeptide called angiotensin I from a plasma protein in the blood called angiotensinogen. A converting enzyme in the blood removes two amino acids from the angiotensin I polypeptide leaving an eight amino acid polypeptide called angiotensin II. Angiotensin II has numerous effects on the smooth muscle layers of arterioles, including causing vasoconstriction. Further, an indirect effect of an increase in angiotensin II increases blood volume. Blood volume is increased because angiotensin II stimulates secretion of aldosterone from the adrenal cortex which, in turn, causes an increase in salt and water retention in the kidneys. Angiotensin II also stimulates thirst centers in the hypothalamus causing more water to be ingested. The increase in blood volume and the corresponding vasoconstriction cause an increase in blood pressure and hence a volume overload on the heart which causes further deterioration of the heart condition.
Another response is also related to congestive heart failure. Baroreceptors, referred to as stretch receptors, reside in the aortic arch and carotid sinuses. The baroreceptors are essentially pressure sensors sensing blood pressure in that area. The baroreceptors provide physiological feedback in two ways. First, in response to a reduction in blood pressure, the baroreceptors provide a neurohormonal feedback response which acts to increase the heart rate in an attempt to increase cardiac output . The increased heart rate causes the heart to work harder which, in turn, causes the heart muscle to stretch further. Also, a reduction in pressure caused by a reduction in cardiac output causes the baroreceptors to provide a feedback response which acts to constrict the distal vasculature thus increasing pressure in that area.
It can thus be seen that impairment of heart function can lead to a cyclical feedback response which increases, rather than reduces, the impairment. Such a cyclical feedback response is sometimes referred to as a cascade . For instance, if the heart muscle is stressed, the heart works harder and begins to stretch. This reduces the efficiency of the heart in the following way. Muscles are thought of as being composed of many fibers which contract and lengthen to accomplish muscular action. Each fiber includes many densely packed subunits referred to as myofibrils which are on the order of 1 μm in diameter and extend in parallel from one end of the muscle fiber to the other. Each myofibril has spaced regions of thick filaments (about 110A thick) and thin filaments (about 50-60A thick) . The thick filaments are formed of a protein, myosin, and the thin filaments are formed of a protein, actin. The actin and myosin filaments overlap in regions periodically spaced along the myofibrils. The units in the repeated overlapping pattern are referred to as sarcomeres .
Contraction of a muscle fiber results from shortening of the myofibrils which form the muscle fiber. The myofibrils are shortened, but the individual filaments in the myofibrils do not decrease in length. Instead, the actin and myosin filaments slide longitudinally relative to one another to shorten the overall length of the myofibrils. Sliding occurs as a result of cross-bridges extending from the myosin toward the actin attaching to the actin at bonding sites. The cross bridges are oriented to draw overlapping actin filaments on either longitudinal side of the myosin filament toward the longitudinal center of the myosin filament. When the muscle fiber is stretched such that the actin and myosin only overlap a short distance, only a small number of cross-bridges are available for bonding to the adjacent actin, and contraction is highly inefficient. When the muscle is stretched to a point where the actin and myosin filaments no longer overlap, contraction is rendered impossible.
This inefficient or impaired heart function causes blood pressure in the areas of both the kidneys and the baroreceptors to decrease. The feedback response generated by the kidneys causes further overload and stress on the heart . The feedback response generated by the baroreceptors causes increased heart rate . Both of these feedback responses cause the heart to work harder, causing further stretching of the heart muscle and thus leading to greater inefficiencies. In response, the feedback responses become even more acute -- and the cascade continues.
This cascade effect, which is a natural progression of congestive heart failure, leads to increased muscle mass and stretching of the heart muscle fibers which, in turn, leads to muscular hypertrophy of the left ventricle. The hypertrophy is a compensatory mechanism which, if maintained at a given level such that muscle fibers maintain inherent contractile properties (i.e., actin-myosin overlap), can be beneficial for maintaining proper heart function. However, prolonged and continuous stretching causes muscular fatigue and reduced muscle performance as explained by the known Frank-Starling mechanism.
SUMMARY OF THE INVENTION An apparatus and method restrict elongation of heart muscle tissue in a wall of a heart having a chamber. A plurality of biocompatible and implantable elongate strips are configured to be connected to the heart wall and disposed about the chamber such that the elongate strips are arranged in spaced relation to one another. The elongate strips are bendable and are sufficiently resistant to elongation such that natural - 5 - stretching of the heart wall does not cause elongation of the plurality of strips.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A is a side sectional view of a heart. FIG. IB is a greatly enlarged sectional view of a portion of the heart shown in FIG. 1A.
FIG. 2 illustrates a retention strip in accordance with one aspect of the present invention.
FIG. 3 illustrates the retention strip shown in FIG. 2 embedded in the heart wall.
FIG. 4 illustrates a plurality of the strips as shown in FIG. 2 embedded in the wall of the left ventricle .
FIG. 5 illustrates a second embodiment of a retention mechanism in accordance with one aspect of the present invention.
FIG. 6A shows the retention mechanism illustrated in FIG. 5 deployed on the outer surface of the left ventricle. FIG. 6B is a sectional view of a portion of the heart wall shown in FIG. 6A.
FIG. 7 illustrates another embodiment of a monitoring system in accordance with one aspect of the present invention. FIG. 8 illustrates a portion of the monitoring system shown in FIG. 7 in schematic and partial block diagram form.
FIG. 9 illustrates another embodiment of a monitoring and control system in schematic and partial block diagram form.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
FIG. 1A illustrates a portion of a heart 10. FIG. 1A illustrates a plurality of chambers in heart 10 including right ventricle 12 and left ventricle 14. FIG. 1A also illustrates heart wall 16 which extends around chambers 12 and 14, and separates chambers 12 and 14. As discussed in the background portion above, congestive heart failure can lead to hypertrophy of the muscle fibers in heart 10, particularly those surrounding left ventricle 14.
FIG. IB illustrates a greatly enlarged sectional view of a portion of wall 16 of heart 10 shown in FIG. 1A. FIG. IB is taken from the portion labeled IB in FIG. 1A. FIG. IB illustrates that wall 16 is formed of an endocardium layer 18 which comprises the inner tissue of heart wall 16. Heart wall 16 also includes an epicardium layer 20 which comprises the outer tissue in heart wall 16. Mid-wall portion 22 comprises a portion of wall 16 between the endocardium 18 and epicardium 20. The pericardium is a double- walled sac which encloses the heart. The inner layer of the pericardial sac comprises the epicardium 20.
Photomicrographs available from the American Heart Association libraries show that the alignment of cardiac muscle fibers are generally perpendicular to the ventricular cavity wall in the endocardium 18 and epicardium 20. Also, the muscle fibers are typically nearly parallel to the ventricular cavity wall in the mid-wall portion 22. During hypertrophy of the muscular wall 16 around the left ventricle 14, the muscle fibers stretch and elongate in a direction generally parallel to their longitudinal orientation. Thus, the muscle fibers in the endocardium 18 and epicardium 20 elongate in a direction generally perpendicular to the ventricular cavity wall. Also, the muscle fibers in the mid-wall region 22 elongate in a direction generally parallel to the ventricular cavity wall. Additional muscle fibers also develop. All of these effects contribute to an increase in muscle mass and stretching of the heart muscle fibers.
FIG. 2 illustrates a retention strip 24 in accordance with one aspect of the present invention. Retention strip 24, in one preferred embodiment, includes a generally longitudinal strut 26 with a first set of protrusions 28, 30 and 32 extending from strut 26 in a first direction and a second plurality of protrusions 34 and 36 extending from longitudinal strut 26 in a second direction, generally opposite the first direction. While protrusions 28, 30 and 32 are shown to have a generally T-shaped conformation, and while protrusions 34 and 36 have a generally linear conformation, it should be noted that all of struts 28- 36 could either have a T conformation or a linear conformation .
Retention strip 24 is also shown having a plurality of apertures 38 which are used for suturing retention strip 24 in place. Of course, the number and placement of the suture apertures 38 shown in FIG. 2 is illustrative only. More or less apertures 38, and apertures having different placement on retention strip 24 are contemplated as well.
Also, while only three protrusions 28, 30, and 32 are shown and two protrusions 34 and 36 are shown, any suitable number of protrusions can be used on either side of retention strip 24. Strut 26 and protrusions 28-36 are preferably formed of a material which allows repeated bending cycles, without permanent deformation or breakage. However, strut 26 and protrusions 28-36 are also preferably formed of a material which exhibits high resistance to elongation in the longitudinal direction. Suitable materials include collagen, or biocompatable and implantable polymer strips, as well as - 8 - biocompatable and implantable metals, cartilage, or composite materials, Nitinol and bovine and porcine byproducts, as examples.
FIG. 3 illustrates a portion of wall 16 with retention strip 24 implanted therein. In a preferred embodiment, longitudinal strut 26 is implanted in the mid-wall region 22 of wall 16. Protrusions 28, 30 and 32 (and any other number of protrusions) extend into the endocardium layer 18, while protrusions 34 and 36 (and any other suitable number of protrusions) extend into the epicardium layer 20. Retention strip 24 is then sutured in place by an appropriate suturing technique using apertures 38 in retention strip 24. Retention strip 24 preferably extends throughout substantially the entire longitudinal length of the ventricular cavity wall, such as from the base to the apex of the ventricular cavity wall .
FIG. 4 illustrates a plurality of retention strips 24 embedded in wall 16 about left ventricle 14. Retention strips 24 are preferably arranged at regular intervals about left ventricle 14 to encircle left ventricle 14 in wall 16. Such placement forms a restrictive cage around left ventricle 14 of heart 10. Strips 24 thus provide very little, or no impedance to the natural contractile motion of the heart. However, fixturing of retention strips 24 to the tissue of the heart with sutures prevents enlargement or substantially eliminates enlargement and extensive stretch of the muscle fibers . Since longitudinal strut 26 is substantially resistant to elongation in its longitudinal direction, it helps to prevent elongation of the muscle fibers in mid-wall region 22. Also, since protrusions 28, 30 and 32 are highly resistant to elongation in their longitudinal directions, they greatly inhibit elongation or stretch of the muscle fibers in endocardium layer 18. Similarly, since protrusions 34 and 36 are highly resistant to elongation in their longitudinal direction, they greatly inhibit elongation or stretch of the muscle fibers in endocardium layer 20.
Placement of retention strips 24 in the positions illustrated in FIG. 4 thus restrict the progression of congestive heart failure of the muscle due to the pressure overload on left ventricle 14. The muscle is supported in such a way that it is not allowed to progressively increase its mass, and also such that uncontrolled stretching is limited by physically restricting its growth and stretch. Thus, heart failure can be controlled. Further, since the recruitable muscle mass can still perform a satisfactory job due to the limited constraint on its contraction, no additional or compensatory muscle mass is generated, which also restricts growth of new muscle tissue in wall 16. This aspect of the present invention thus reduces fatigue of the heart muscle and allows for natural regeneration of healthy cardiac tissue. Also, it is believed that supporting the cardiac muscle tissue relives tension on the chordae tendinae which, in turn, helps prevent mitral valve regurgitation which prevents higher mean atrial pressures and thus pulmonary edema.
FIG. 5 illustrates another embodiment of a retention device 40 in accordance with another aspect of the present invention. With progressive congestive heart failure, heart 10 may already have started to hypertrophy and thus may be vulnerable to trauma. Thus, extensive incision in heart 10 may be undesirable. In that case, retention device 40 can be used by attaching it to the epicardial surface of heart 10 with only - 10 - minimal intrusion into the heart muscle (such as with sutures, adhesives, staples, or other connection techniques) .
Retention device 40 includes a first generally circular strap 42 and a second generally circular strap 44. Straps 42 and 44 are connected to one another by a plurality of generally longitudinal straps 46, 48, 50, 52 and 54. Straps 46-54 are preferably attached to circular strips 42 and 44 by a suitable adhesive, by welding, or by another suitable mechanism, or are formed integrally with circular straps 42. Straps 42-54 are preferably formed of collagen, polymer or metal fibers which exhibit the capability of undergoing many bending cycles, without permanent deformation of damage. Straps 42-54 are also formed to exhibit high resistance to elongation in the generally longitudinal directions. In addition, straps 42-54 have a plurality of apertures 56 therein which are used to attach retention device 40 to the heart wall 16 with an appropriate suturing technique. Of course, as with the embodiment illustrated in FIGS. 2-4, any suitable number of straps 42-54 can be used. The arrangement of straps 42-54 can also be changed as desired. Further, the number and placement of suture apertures 56 can be changed to any suitable number and location on straps 42-54.
FIG. 6A illustrates retention device 40 deployed on wall 16 of left ventricle 14. FIG. 6A illustrates that, in one preferred embodiment, straps 42-54 are periodically, and alternately, sutured to the outer surface of epicardium 20, and embedded within wall
16. FIG. 6A also illustrates that more longitudinal straps can be used than are illustrated in FIG. 5. This simply illustrates that any desired number of longitudinal straps can be used. In the preferred - 11 - embodi ent, in the areas where straps 42-54 are embedded in wall 16, they are embedded only in the epicardium layer 20 such that extensive incisions into wall 16 need not be made . FIG. 6B better illustrates embedding of straps
42-54 in the wall 16 of heart 10. FIG. 6B is a greatly enlarged cross-section of wall 16 taken in the region labeled 6B in FIG. 6A. FIG. 6B illustrates that strap 46, at alternate portions 58 is simply sutured to the exterior of epicardium layer 20, while at other portions 60 is embedded within the epicardium layer 20. Of course, straps 42-54 could be embedded more deeply in the wall 16. However, embedding in epicardial layer 20 is preferred. As with the embodiment illustrated in FIGS. 2-
4, retention device 40 restricts the progression of failure of heart muscle 16 due to pressure overload on the left ventricle 14 of heart 10. Heart 10 is not allowed to progressively increase its mass and since the uncontrolled stretching of the heart muscle is physically restricted, heart failure can be controlled. Further, since the recruitable muscle mass is still capable of operating satisfactorily, no additional, compensatory muscle mass needs to be generated. Retention device 40 thus restricts growth of new muscle. Further, retention device 40 allows for minimal internal damage to heart 10.
FIG. 7 illustrates another embodiment of retention device 40 in accordance with one aspect of the present invention. Retention device 40, shown in FIG. 7, is similar to that shown in FIG. 5, and similar items are similarly numbered. However, the longitudinal straps 46-54 (only four of which are shown in FIG. 7) are each provided with a plurality of sensors 62 which - 12 - are configured to sense stretching, and/or other physiologic parameters, such as electrical activity, acceleration or physicochemical activity, of the cardiac muscle wall 16. In the illustration of FIG. 7, sensors 62 are only provided on longitudinal strap 48, it will be appreciated that, in a preferred embodiment, sensors 62 are similarly disposed on each of the straps 42-54. Sensors 62 are preferably wire bond strain gauges, piezopolymer strips, or other strain measuring sensors. As is generally known, some such strain gauges are provided with a resistive bridge having a signal, such as a voltage, applied thereacross . As strain on the bridge changes, the values of signals received from the bridge change in a differential manner. In piezopolymer elements, application of a mechanical stress to the device generates electric polarization which can also be sensed. Thus, each sensor 62 provides one or more conductors 64 which carry signals indicative of the stretching of muscle wall 16. Such conductors are preferably provided through a suitable cable 66 to monitor circuit 68 which, in turn, is coupled to a user input/output (I/O) device 70.
In one preferred embodiment, the strain information captured by the signals conducted by conductors 64 to monitor circuit 68 is processed to obtain a total stretch response in the myocardium of heart 10. Such processing preferably occurs in monitor circuit 68 and is described below. The total stretch response is preferably monitored for variations and thus provides information about the stretching and condition of heart 10. This information is preferably used for the treatment and management of the heart failure condition, either by itself through observation, or used to generate a feedback signal which can be used to pace - 13 - heart 10 for maximal contraction (which is described in greater detail with respect to FIG. 9) .
User I/O device 70 is preferably any suitable I/O device, such as a cathode ray tube, an LCD display, a strip or other printer, or any other suitable I/O device. I/O device 70 may also allow user input functions by including a keypad, a keyboard, or other user actuable elements.
FIG. 8 illustrates a more detailed block diagram of one embodiment of monitor circuit 68. Monitor circuit 68 preferably includes a plurality of differential amplifiers 72, 74 and 76, a circuit (such as a summing amplifier, multiplexer, etc.) 78 and a microprocessor or microcontroller based circuit 80. Of course, monitor circuit 68 may also include other signal filtering and amplification, and other general signal conditioning circuitry, which is generally known for conditioning signals from strain sensors and is not described here in detail. In the embodiment illustrated in FIG. 8, differential amplifiers 72-76 are provided for amplifying the signals received from strain sensors 62. In one preferred embodiment, each strain sensor 62 has a corresponding differential amplifier. Alternatively, of course, multiplexing circuity can be used to switch the signals from sensors 62 into a single, or into one or more of the differential amplifiers. In any case, the output signals from differential amplifiers 72-76 are provided to circuit 78. In the embodiment in which circuit 78 is a summing amplifier, the signals are summed in a desired manner to obtain the total stretch response of the myocardium of heart 10. The signal from amplifier 78 is provided to microprocessor 80 where it is preferably corrected for any non-linearities and - 14 - temperature affects, in a known manner. Microprocessor 80 then generates a suitable output signal to user I/O device 70.
In another embodiment in which circuit 78 is a multiplexer, each of the signals from amplifiers 72-76 are switched into microprocessor 80 under the control of microprocessor 80. Alternatively, circuit 78 can also be eliminated. In that embodiment, the outputs from amplifiers 72-76 are provided as discrete inputs to microprocessor 80. It should also be noted that other inputs can be provided to microprocessor 80 as well, such as EKG information, blood pressure information, or other sources of information. In any case, microprocessor 80 generates a signal to user I/O device 70 based on the signals from amplifiers 72-76.
FIG. 9 illustrates another embodiment of a monitoring and control system 82 in accordance with one aspect of the present invention. Some items in system 82 are similar to those shown in FIGS. 7 and 8 and are similarly numbered. In system 82, each sensor 62 is provided with a strain sensing element 84, as discussed above, and an excitation electrode 86. Excitation electrodes 86 are preferably conventional pacing electrodes capable of delivering pacing voltages to the myocardium of heart 10. While the sensing elements 84 and pacing electrodes 86 are shown attached to one another in FIG. 9, it should be noted that they can be separated from one another, but are preferably closely proximate one another when deployed on one of straps 42- 54.
In one preferred embodiment, microprocessor 80 receives the stretch response information from sensor elements 84 which indicates not only long term stretching of the heart muscle fibers, but which also - 15 - indicates contractile motion of the heart 10 in a pulsatile fashion. Based upon this information, microprocessor 80 generates a plurality of feedback signals which are provided to each of pacing electrodes 86. The feedback signals are used to energize pacing electrodes 86 to deliver the necessary pacing voltages to the myocardium of heart 10 in order to pace heart 10. In one preferred embodiment, microprocessor 80 simply energizes all of electrodes 86 at one time to cause contraction of the heart muscle. In another preferred embodiment, however, the microprocessor 80 selectively and sequentially energizes each of the excitation electrodes 86 in order to sequentially pace different sets of electrodes 86 to achieve optimal contraction of the ventricles. In that embodiment, the output of each of differential amplifiers 72, 74 and 76 can be individually provided to microprocessor 80, as well as through, for example, a summing amplifier 78. Microprocessor 80, in a preferred embodiment, also calculates and delivers appropriate pacing voltages to the various sets of excitation electrodes 86 being controlled.
As with the other embodiments discussed herein, system 82, when used in conjunction with retention device 40 restricts the progression of failure of the muscle of heart 10 due to the pressure overload in the left ventricle 14. The muscle in heart 10 is preferably supported such that it is not allowed to progressively increase its mass, and so as to restrict uncontrolled stretch of the heart muscle in order to control heart failure. Since the muscle is not allowed to reach a point of destructive stretching, the muscle fibers maintain their inherent contractile properties
(actin-myosin overlap) and the progression to failure - 16 -
(or cascade) can be stopped. Also, since the recruitable muscle mass is still performing satisfactorily, no additional or compensatory muscle mass needs to be generated, thus further restricting growth of new muscle .
In another preferred embodiment, the present invention is used to deliver a drug or other therapeutic agent to the tissue with which it is used. For example, in one embodiment, the struts, protrusions, retention strips, etc. are coated or impregnated with or otherwise provided with the therapeutic agent which is preferably engineered to be released into the adjacent tissue over time. Such drugs or therapeutic agents illustratively include genetic therapeutic agents like growth factors, angiogenics, angiotensin converting enzymes, or contractibility promoters (such as that sold under the name Digitalis) or other suitable drugs.
In addition, it is believed that the heart muscle can benefit from suturing or other manipulations of the heart muscle in accordance with the present invention. This benefit results from myocardial revascularization which is a known angiogenic effect which regenerates cardiac tissue.
The present invention reduces fatigue of the heart and allows for natural regeneration of healthy cardiac tissue, or increases the efficiency of pharmacologically administered treatments. It is also believed that supporting the cardiac muscle in this way relieves tension on the chordae tendinae which in turn prevents mitral valve regurgitation thus preventing higher mean atrial pressures and pulmonary edema. All of these factors contribute to the cascade of failures in organs and systems associated with congestive heart failure. Once the relaxed heart muscle has regained - 17 - many of its own contractile properties, it can be weaned from the pacing routine.
It should also be noted that the present invention contemplates implementing the techniques and devices described herein not only on the left ventricle, but also on the right ventricle or the other chambers of the heart. Further, the present invention can be implemented on any desired combination of chambers.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

Claims

- 18 -WHAT IS CLAIMED IS:
1. An apparatus for relieving stress of heart muscle tissue in a wall of a heart having a chamber, the muscle tissue having an epicardium layer, an endocardium layer and a midwall portion between the epicardium and endocardium layers, the epicardium layer, the endocardium layer and the midwall portion extending generally longitudinally to form the wall of the heart, the apparatus comprising: a plurality of biocompatible and implantable elongate strips, elongate in a longitudinal direction, configured to be connected to the heart wall and disposed about the chamber such that the elongate strips are arranged in spaced relation to one another, the elongate strips being bendable and being sufficiently resistant to elongation that natural stretching of the heart wall does not cause elongation of the plurality of strips .
2. The apparatus of claim 1 wherein the elongate strips are resistant to elongation in the longitudinal direction.
3. The apparatus of claim 1 wherein each of the elongate strips comprises: a longitudinal strut; and a first plurality of protrusions extending from the longitudinal strut in a first direction, the first protrusions being sufficiently resistant to elongation in the first direction such that natural stretching of the heart wall does not - 19 - cause elongation of the first protrusions in the first direction.
4. The apparatus of claim 3 wherein each of the elongate strips comprises : a second plurality of protrusions extending from the longitudinal strut in a second direction, generally opposite the first direction, the second protrusions being sufficiently resistant to elongation in the second direction such that natural stretching of the heart wall does not cause elongation of the second protrusions in the second direction.
5. The apparatus of claim 4 wherein the longitudinal strut and the first and second protrusions are arranged such that when the longitudinal strut is positioned longitudinally in the midwall portion, the first protrusions extend into the epicardium layer and the second protrusions extend into the endocardium layer.
6. The apparatus of claim 5 wherein the first protrusions have a generally linear conformation.
7. The apparatus of claim 5 wherein the second protrusions have a generally T-shaped conformation.
8. The apparatus of claim 5 wherein the longitudinal strut and the first and second protrusions define a plurality of apertures suitable for receiving sutures .
9. The apparatus of claim 1 wherein the plurality of elongate strips are connected to the epicardium layer.
10. The apparatus of claim 9 wherein the plurality of strips are connected to one another, in spaced -20 - relation to one another to from a cage structure sized to be disposed about the chamber.
11. The apparatus of claim 10 wherein the plurality of strips carry a plurality of sensors configured to sense physiological parameters in the wall of the heart and provide sensor signals indicative of the sensed parameters .
12. The apparatus of claim 11 wherein the plurality of sensors are configured to sense stretching of the wall of the heart and provide the sensor signals indicative of the sensed stretching.
13. The apparatus of claim 12 and further comprising: a monitor coupled to the plurality of sensors to receive the sensor signals and provide a monitor signal based on the sensor signals; and an input/output device, coupled to the monitor, to receive the monitor signal and provide user observable indicia, indicative of the sensed stretching based on the monitor signal .
14. The apparatus of claim 13 and further comprising: a plurality of electrodes carried by the plurality of strips; and wherein the monitor includes a controller coupled to the electrodes to control application of excitation signals to the electrodes, the electrodes stimulating the heart muscle in response to the excitation signals.
15. The apparatus of claim 14 wherein the controller is coupled to the sensors and is configured - 21 - to apply the excitation signals based on the sensor signals .
16. The apparatus of claim 15 wherein the controller is configured to apply the excitation signals to all electrodes substantially simultaneously.
17. The apparatus of claim 15 wherein the controller is configured to apply the excitation signals to the sensors sequentially.
18. The apparatus of claim 17 wherein the controller is configured to apply the excitation signals to sets of the sensors sequentially.
19. The apparatus of claim 11 wherein the strips define a plurality of apertures therein sized to receive sutures .
20. The apparatus of claim 1 wherein the elongate strips include a drug releasably coupled thereto.
21. A method of restricting elongation of heart muscle tissue in a wall of a heart having a chamber, the muscle tissue having an epicardium layer, an endocardium layer and a midwall portion between the epicardium and endocardium layers, the epicardium layer, the endocardium layer and the midwall portion extending generally longitudinally to form the wall of the heart, the method comprising: providing a plurality of biocompatible and implantable elongate strips, elongate in a longitudinal direction, the elongate strips being bendable and being sufficiently resistant to elongation in the longitudinal direction such that natural stretching of the heart wall does not cause elongation of the plurality of strips; and - 22 - connecting the elongate strips to the heart wall and about the chamber such that the elongate strips are arranged in spaced relation to one another.
22. The method of claim 21 wherein providing a plurality of elongate strips comprises providing the elongate strips such that each of the elongate strips comprises : a longitudinal strut ; a first plurality of protrusions extending from the longitudinal strut in a first direction, the first protrusions being sufficiently resistant to elongation in the first direction such that natural stretching of the heart wall does not cause elongation of the first protrusions in the first direction; and a second plurality of protrusions extending from the longitudinal strut in a second direction, generally opposite the first direction, the second protrusions being sufficiently resistant to elongation in the second direction such that natural stretching of the heart wall does not cause elongation of the second protrusions in the second direction.
23. The method of claim 22 wherein connecting the elongate strips to the heart comprises: implanting the longitudinal strut longitudinally in the midwall portion; arranging the strip such that the first protrusions extend into the epicardium layer and the second protrusions extend into the endocardium layer; and - 23 - attaching the longitudinal strut and the first and second protrusions to surrounding tissue in the heart wall.
24. The method of claim 23 wherein attaching comprises : attaching utilizing a method which promotes revascularization of the tissue in the heart wall.
25. The method of claim 23 wherein the longitudinal strut and the first and second protrusions define a plurality of apertures, and wherein attaching comprises : suturing the longitudinal strut and the first and second protrusions to the surrounding tissue through the apertures .
26. The method of claim 21 wherein the plurality of strips are connected to one another, in spaced relation to one another to from a cage structure, and wherein connecting comprises: attaching the cage structure to the heart wall around the chamber.
27. The method of claim 26 wherein attaching comprises : implanting first portions of the strips in the heart wall; and connecting second portions of the strips between the between the first portions, to an exterior surface of the epicardium layer.
28. The method of claim 27 wherein implanting comprises : implanting the first portions in the epicardium layer. - 24 -
29. The method of claim 26 wherein providing a plurality of strips comprises: providing a plurality of sensors carried by the elongate strips; sensing, with the sensors, stretching of the wall of the heart; and providing sensor signals indicative of the sensed stretching.
30. The method of claim 29 and further comprising: providing user observable indicia, indicative of the sensed stretching, based on the sensor signals.
31. The method of claim 30 wherein providing a plurality of elongate strips further comprises: providing a plurality of electrodes carried by the plurality of strips; and controlling application of excitation signals to the electrodes, the electrodes stimulating the heart muscle in response to the excitation signals.
32. The method of claim 31 wherein controlling application of excitation signals comprises: applying the excitation signals based on the sensor signals.
33. The method of claim 32 wherein applying the excitation signals comprises: applying the excitation signals to all electrodes substantially simultaneously.
34. The method of claim 32 wherein applying the excitation signals comprises: applying the excitation signals to the sensors sequentially. - 25 -
35. The method of claim 34 wherein applying the excitation signals sequentially comprises: applying the excitation signals to sets of the sensors sequentially.
36. The method of claim 26 wherein the strips define a plurality of apertures, and wherein attaching the cage structure comprises: suturing the strips to the heart wall through the apertures .
PCT/US1999/008713 1998-04-22 1999-04-20 System for stress relieving the heart muscle and for controlling heart function WO1999053977A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000544377A JP4190730B6 (en) 1998-04-22 1999-04-20 A system to control cardiac function by relieving myocardial stress
EP99917645A EP1073488A1 (en) 1998-04-22 1999-04-20 System for stress relieving the heart muscle and for controlling heart function
CA002329735A CA2329735A1 (en) 1998-04-22 1999-04-20 System for stress relieving the heart muscle and for controlling heart function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/064,370 US6110100A (en) 1998-04-22 1998-04-22 System for stress relieving the heart muscle and for controlling heart function
US09/064,370 1998-04-22

Publications (1)

Publication Number Publication Date
WO1999053977A1 true WO1999053977A1 (en) 1999-10-28

Family

ID=22055469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/008713 WO1999053977A1 (en) 1998-04-22 1999-04-20 System for stress relieving the heart muscle and for controlling heart function

Country Status (4)

Country Link
US (2) US6110100A (en)
EP (1) EP1073488A1 (en)
CA (1) CA2329735A1 (en)
WO (1) WO1999053977A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190408B1 (en) 1998-03-05 2001-02-20 The University Of Cincinnati Device and method for restructuring the heart chamber geometry
US6221103B1 (en) 1996-01-02 2001-04-24 The University Of Cincinnati Device and method for restructuring heart chamber geometry
WO2001067985A1 (en) * 2000-03-10 2001-09-20 Paracor Surgical, Inc. Expandable cardiac harness for treating congestive heart failure
US6520904B1 (en) 1996-01-02 2003-02-18 The University Of Cincinnati Device and method for restructuring heart chamber geometry
US6592619B2 (en) 1996-01-02 2003-07-15 University Of Cincinnati Heart wall actuation device for the natural heart
JP2005523049A (en) * 2002-01-31 2005-08-04 シメッド ライフ システムズ インコーポレイテッド Medical device for releasing biologically active substances
EP1594569A2 (en) * 2003-01-27 2005-11-16 Corassist Cardiovascular Ltd. In vivo device for improving diastolic ventricular function
US6997951B2 (en) 1999-06-30 2006-02-14 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
US7044967B1 (en) 1999-06-29 2006-05-16 Edwards Lifesciences Ag Device and method for treatment of mitral insufficiency
US7081084B2 (en) 2002-07-16 2006-07-25 University Of Cincinnati Modular power system and method for a heart wall actuation system for the natural heart
US7090695B2 (en) 1999-06-30 2006-08-15 Edwards Lifesciences Ag Method for treatment of mitral insufficiency
WO2008144696A1 (en) 2007-05-21 2008-11-27 Bioventrix (Aka Chf Technologies, Inc.) Methods and implants for treatment of cardiac failure
EP1629794A3 (en) * 2000-01-31 2009-07-01 Edwards Lifesciences AG Percutaneous mitral annuloplasty and cardiac reinforcement
US7666224B2 (en) 2002-11-12 2010-02-23 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US7678145B2 (en) 2002-01-09 2010-03-16 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US7722523B2 (en) 1998-07-29 2010-05-25 Edwards Lifesciences Llc Transventricular implant tools and devices
US7766812B2 (en) 2000-10-06 2010-08-03 Edwards Lifesciences Llc Methods and devices for improving mitral valve function
US7993258B2 (en) 2001-07-16 2011-08-09 Corassist Cardiovascular Ltd. In-vivo method and device for improving diastolic function of the left ventricle
US8092367B2 (en) 2001-09-07 2012-01-10 Mardil, Inc. Method for external stabilization of the base of the heart
US8226711B2 (en) 1997-12-17 2012-07-24 Edwards Lifesciences, Llc Valve to myocardium tension members device and method
US8579798B2 (en) 1998-09-21 2013-11-12 Edwards Lifesciences, Llc External cardiac stress reduction method

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406420B1 (en) * 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US7883539B2 (en) 1997-01-02 2011-02-08 Edwards Lifesciences Llc Heart wall tension reduction apparatus and method
US20030045771A1 (en) * 1997-01-02 2003-03-06 Schweich Cyril J. Heart wall tension reduction devices and methods
US6045497A (en) 1997-01-02 2000-04-04 Myocor, Inc. Heart wall tension reduction apparatus and method
US6077214A (en) * 1998-07-29 2000-06-20 Myocor, Inc. Stress reduction apparatus and method
US6050936A (en) 1997-01-02 2000-04-18 Myocor, Inc. Heart wall tension reduction apparatus
US6110100A (en) * 1998-04-22 2000-08-29 Scimed Life Systems, Inc. System for stress relieving the heart muscle and for controlling heart function
US6587734B2 (en) * 1998-11-04 2003-07-01 Acorn Cardiovascular, Inc. Cardio therapeutic heart sack
US6702732B1 (en) 1999-12-22 2004-03-09 Paracor Surgical, Inc. Expandable cardiac harness for treating congestive heart failure
US7296577B2 (en) * 2000-01-31 2007-11-20 Edwards Lifescience Ag Transluminal mitral annuloplasty with active anchoring
US6989028B2 (en) 2000-01-31 2006-01-24 Edwards Lifesciences Ag Medical system and method for remodeling an extravascular tissue structure
US6537198B1 (en) 2000-03-21 2003-03-25 Myocor, Inc. Splint assembly for improving cardiac function in hearts, and method for implanting the splint assembly
US7172615B2 (en) * 2000-05-19 2007-02-06 Coapt Systems, Inc. Remotely anchored tissue fixation device
US7510566B2 (en) * 2000-05-19 2009-03-31 Coapt Systems, Inc. Multi-point tissue tension distribution device and method, a chin lift variation
US6485503B2 (en) * 2000-05-19 2002-11-26 Coapt Systems, Inc. Multi-point tissue tension distribution device, a brow and face lift variation, and a method of tissue approximation using the device
US20050119694A1 (en) * 2000-05-19 2005-06-02 Jacobs Daniel I. Remotely anchored tissue fixation device and method
US20050095268A1 (en) * 2000-06-12 2005-05-05 Acorn Cardiovascular, Inc. Cardiac wall tension relief with cell loss management
US6343605B1 (en) * 2000-08-08 2002-02-05 Scimed Life Systems, Inc. Percutaneous transluminal myocardial implantation device and method
US6673009B1 (en) * 2000-11-08 2004-01-06 Acorn Cardiovascular, Inc. Adjustment clamp
US6810882B2 (en) 2001-01-30 2004-11-02 Ev3 Santa Rosa, Inc. Transluminal mitral annuloplasty
US7510576B2 (en) 2001-01-30 2009-03-31 Edwards Lifesciences Ag Transluminal mitral annuloplasty
US6622730B2 (en) 2001-03-30 2003-09-23 Myocor, Inc. Device for marking and aligning positions on the heart
US6923646B2 (en) * 2001-04-18 2005-08-02 Air Techniques, Inc. Process and apparatus for treating an exhaust stream from a dental operatory
WO2003022176A2 (en) 2001-09-10 2003-03-20 Paracor Medical, Inc. Cardiac harness
US7060023B2 (en) * 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
US6695769B2 (en) 2001-09-25 2004-02-24 The Foundry, Inc. Passive ventricular support devices and methods of using them
EP1446069A1 (en) * 2001-10-31 2004-08-18 Paracor Surgical, Inc. Heart failure treatment device
SE524709C2 (en) * 2002-01-11 2004-09-21 Edwards Lifesciences Ag Device for delayed reshaping of a heart vessel and a heart valve
AU2002360066B2 (en) * 2001-12-28 2008-11-06 Edwards Lifesciences Ag Delayed memory device
US7022063B2 (en) 2002-01-07 2006-04-04 Paracor Medical, Inc. Cardiac harness
US7174896B1 (en) 2002-01-07 2007-02-13 Paracor Medical, Inc. Method and apparatus for supporting a heart
US20030142676A1 (en) * 2002-01-25 2003-07-31 Raymond Zeisz Method and apparauts for admission control in packet switch
US7850729B2 (en) 2002-07-18 2010-12-14 The University Of Cincinnati Deforming jacket for a heart actuation device
US20040059180A1 (en) * 2002-09-23 2004-03-25 The University Of Cincinnati Basal mounting cushion frame component to facilitate extrinsic heart wall actuation
AU2003261252A1 (en) * 2002-07-26 2004-02-16 Myomend, Inc. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
US6988982B2 (en) * 2002-08-19 2006-01-24 Cardioenergetics Heart wall actuation system for the natural heart with shape limiting elements
US7087064B1 (en) 2002-10-15 2006-08-08 Advanced Cardiovascular Systems, Inc. Apparatuses and methods for heart valve repair
US7736299B2 (en) 2002-11-15 2010-06-15 Paracor Medical, Inc. Introducer for a cardiac harness delivery
US9149602B2 (en) 2005-04-22 2015-10-06 Advanced Cardiovascular Systems, Inc. Dual needle delivery system
US7485143B2 (en) * 2002-11-15 2009-02-03 Abbott Cardiovascular Systems Inc. Apparatuses and methods for heart valve repair
US7981152B1 (en) 2004-12-10 2011-07-19 Advanced Cardiovascular Systems, Inc. Vascular delivery system for accessing and delivering devices into coronary sinus and other vascular sites
US7335213B1 (en) 2002-11-15 2008-02-26 Abbott Cardiovascular Systems Inc. Apparatus and methods for heart valve repair
US7404824B1 (en) 2002-11-15 2008-07-29 Advanced Cardiovascular Systems, Inc. Valve aptation assist device
US6945978B1 (en) 2002-11-15 2005-09-20 Advanced Cardiovascular Systems, Inc. Heart valve catheter
US8187324B2 (en) 2002-11-15 2012-05-29 Advanced Cardiovascular Systems, Inc. Telescoping apparatus for delivering and adjusting a medical device in a vessel
US7331972B1 (en) 2002-11-15 2008-02-19 Abbott Cardiovascular Systems Inc. Heart valve chord cutter
US20040098116A1 (en) 2002-11-15 2004-05-20 Callas Peter L. Valve annulus constriction apparatus and method
US7883500B2 (en) * 2003-03-26 2011-02-08 G&L Consulting, Llc Method and system to treat and prevent myocardial infarct expansion
WO2004110257A2 (en) 2003-06-09 2004-12-23 The University Of Cincinnati Power system for a heart actuation device
US20060178551A1 (en) * 2003-06-09 2006-08-10 Melvin David B Securement system for a heart actuation device
WO2004110553A1 (en) 2003-06-09 2004-12-23 The University Of Cincinnati Actuation mechanisms for a heart actuation device
EP1646332B1 (en) * 2003-07-18 2015-06-17 Edwards Lifesciences AG Remotely activated mitral annuloplasty system
US7998112B2 (en) 2003-09-30 2011-08-16 Abbott Cardiovascular Systems Inc. Deflectable catheter assembly and method of making same
US20050288715A1 (en) * 2003-11-07 2005-12-29 Lilip Lau Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
DE602004024329D1 (en) * 2003-12-02 2010-01-07 Ciba Spec Chem Water Treat Ltd PREPARATION OF AMIDES
US20050177228A1 (en) * 2003-12-16 2005-08-11 Solem Jan O. Device for changing the shape of the mitral annulus
US20050197699A1 (en) * 2004-02-10 2005-09-08 Jacobs Daniel I. Tissue repair apparatus and method
US20050209542A1 (en) * 2004-03-16 2005-09-22 Jacobs Daniel I Tissue approximation sling and method
US7993397B2 (en) * 2004-04-05 2011-08-09 Edwards Lifesciences Ag Remotely adjustable coronary sinus implant
WO2005099374A2 (en) * 2004-04-05 2005-10-27 Genesee Biomedical, Inc. Method and apparatus for the surgical treatment of congestive heart failure
US7285087B2 (en) * 2004-07-15 2007-10-23 Micardia Corporation Shape memory devices and methods for reshaping heart anatomy
US20060063964A1 (en) * 2004-08-20 2006-03-23 Massen Richard J Micro electromechanical machine-based ventricular assist apparatus
US20060079736A1 (en) 2004-10-13 2006-04-13 Sing-Fatt Chin Method and device for percutaneous left ventricular reconstruction
WO2006055820A2 (en) * 2004-11-19 2006-05-26 G & L Consulting Llc Biodegradable pericardial constraint system and method
US7211110B2 (en) * 2004-12-09 2007-05-01 Edwards Lifesciences Corporation Diagnostic kit to assist with heart valve annulus adjustment
US20060189840A1 (en) * 2005-02-18 2006-08-24 Acorn Cardiovascular, Inc. Transmyocardial delivery of cardiac wall tension relief
US7500989B2 (en) * 2005-06-03 2009-03-10 Edwards Lifesciences Corp. Devices and methods for percutaneous repair of the mitral valve via the coronary sinus
US7766816B2 (en) 2005-06-09 2010-08-03 Chf Technologies, Inc. Method and apparatus for closing off a portion of a heart ventricle
US7338436B1 (en) * 2005-06-27 2008-03-04 Pacesetter, Inc. Implantable cardiac physical motion mapping device
US20080221673A1 (en) * 2005-08-12 2008-09-11 Donald Bobo Medical implant with reinforcement mechanism
US20070038297A1 (en) * 2005-08-12 2007-02-15 Bobo Donald E Jr Medical implant with reinforcement mechanism
WO2007022519A2 (en) 2005-08-19 2007-02-22 Chf Technologies, Inc. Steerable heart implants for congestive heart failure
US8506474B2 (en) 2005-08-19 2013-08-13 Bioventrix, Inc. Method and device for treating dysfunctional cardiac tissue
US20070073391A1 (en) * 2005-09-28 2007-03-29 Henry Bourang System and method for delivering a mitral valve repair device
US7715918B2 (en) 2005-10-18 2010-05-11 University Of Cincinnati Muscle energy converter with smooth continuous tissue interface
US20070173926A1 (en) * 2005-12-09 2007-07-26 Bobo Donald E Jr Anchoring system for medical implant
US7637946B2 (en) 2006-02-09 2009-12-29 Edwards Lifesciences Corporation Coiled implant for mitral valve repair
US20070208217A1 (en) 2006-03-03 2007-09-06 Acorn Cardiovascular, Inc. Self-adjusting attachment structure for a cardiac support device
WO2008091584A2 (en) 2007-01-22 2008-07-31 Cv Devices, Llc Devices, systems and methods for an epicardial cardiac monitoring system
US9782258B2 (en) * 2006-09-08 2017-10-10 The Regents Of The University Of California Intramyocardial patterning for global cardiac resizing and reshaping
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
US20080065205A1 (en) * 2006-09-11 2008-03-13 Duy Nguyen Retrievable implant and method for treatment of mitral regurgitation
US8123668B2 (en) 2006-09-28 2012-02-28 Bioventrix (A Chf Technologies' Company) Signal transmitting and lesion excluding heart implants for pacing defibrillating and/or sensing of heart beat
US7828854B2 (en) * 2006-10-31 2010-11-09 Ethicon, Inc. Implantable repair device
US10085798B2 (en) * 2006-12-29 2018-10-02 St. Jude Medical, Atrial Fibrillation Division, Inc. Ablation electrode with tactile sensor
US8226648B2 (en) 2007-12-31 2012-07-24 St. Jude Medical, Atrial Fibrillation Division, Inc. Pressure-sensitive flexible polymer bipolar electrode
US20080255447A1 (en) * 2007-04-16 2008-10-16 Henry Bourang Diagnostic catheter
US8192351B2 (en) 2007-08-13 2012-06-05 Paracor Medical, Inc. Medical device delivery system having integrated introducer
US8100820B2 (en) 2007-08-22 2012-01-24 Edwards Lifesciences Corporation Implantable device for treatment of ventricular dilation
US8092363B2 (en) 2007-09-05 2012-01-10 Mardil, Inc. Heart band with fillable chambers to modify heart valve function
EP2194888B1 (en) 2007-10-03 2021-04-28 Bioventrix, Inc. System for treating dysfunctional cardiac tissue
EP2217153B1 (en) * 2007-10-19 2021-03-03 Ancora Heart, Inc. Systems for cardiac remodeling
BR112014007686A2 (en) 2011-09-30 2017-04-18 Bioventrix Inc method and system for heart treatment within the patient
EP2906151B1 (en) 2012-10-12 2023-06-21 Mardil, Inc. Cardiac treatment system
CA2912653A1 (en) 2013-05-24 2014-11-27 Bioventrix, Inc. Cardiac tissue penetrating devices, methods, and systems for treatment of congestive heart failure and other conditions
EP3957252A1 (en) 2013-08-30 2022-02-23 Bioventrix, Inc. Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions
WO2015031647A2 (en) 2013-08-30 2015-03-05 Bioventrix, Inc. Cardiac tissue anchoring devices, methods, and systems for treatment of congestive heart failure and other conditions
USD717954S1 (en) 2013-10-14 2014-11-18 Mardil, Inc. Heart treatment device
EP3346926B1 (en) 2015-09-10 2020-10-21 Bioventrix, Inc. Systems for deploying a cardiac anchor
WO2017132516A1 (en) 2016-01-29 2017-08-03 Kevin Van Bladel Percutaneous arterial access to position transmyocardial implant devices and methods
US11529058B2 (en) * 2017-11-29 2022-12-20 Edwards Lifesciences Corporation Atrial stretch measurement for atrial fibrillation prevention

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3827426A (en) * 1971-07-16 1974-08-06 P Sawyer Prosthetic pump
US3983863A (en) * 1975-06-02 1976-10-05 American Hospital Supply Corporation Heart support for coronary artery surgery
EP0303719A1 (en) * 1987-02-23 1989-02-22 Blagoveschensky Gosudarstvenny Meditsinsky Institut Artificial pericardium
WO1997024101A1 (en) * 1996-01-02 1997-07-10 David Boyd Melvin Activation device for the natural heart and method of doing the same
WO1998029041A1 (en) * 1997-01-02 1998-07-09 Myocor, Inc. Heart wall tension reduction apparatus and method
WO1998055165A1 (en) * 1997-06-06 1998-12-10 Woodard John C Cardiac assist device
WO1998058598A1 (en) * 1997-06-21 1998-12-30 Hans Haindl Bag for at least partially enveloping a heart

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR94491E (en) * 1965-10-13 1969-08-22 Philips Massiot Mat Medic Pacemaker.
US3455298A (en) * 1967-04-10 1969-07-15 George L Anstadt Instrument for direct mechanical cardiac massage
US4030509A (en) * 1975-09-30 1977-06-21 Mieczyslaw Mirowski Implantable electrodes for accomplishing ventricular defibrillation and pacing and method of electrode implantation and utilization
US4144889A (en) * 1977-05-31 1979-03-20 Research Corporation Cardiac electrodes for temporary pacing
IT1155105B (en) * 1982-03-03 1987-01-21 Roberto Parravicini PLANT DEVICE TO SUPPORT THE MYOCARDIUM ACTIVITY
US4685446A (en) * 1984-02-21 1987-08-11 Choy Daniel S J Method for using a ventricular assist device
US5095916A (en) * 1985-06-20 1992-03-17 Medtronic, Inc. Cardioversion and defibrillation lead system
SE455164B (en) * 1985-12-05 1988-06-27 Data Promeditech Inc Ab PUMP FOR BIOLOGICAL SCIENCES
SE454942B (en) * 1986-05-22 1988-06-13 Astra Tech Ab HEART HELP DEVICE FOR INOPERATION IN BROSTHALAN
US4781716A (en) * 1987-02-13 1988-11-01 Marc Richelsoph Artificial heart
US4925443A (en) * 1987-02-27 1990-05-15 Heilman Marlin S Biocompatible ventricular assist and arrhythmia control device
US4861330A (en) * 1987-03-12 1989-08-29 Gene Voss Cardiac assist device and method
US4938766A (en) * 1987-08-28 1990-07-03 Jarvik Robert K Prosthetic compliance devices
US4817586A (en) * 1987-11-24 1989-04-04 Nimbus Medical, Inc. Percutaneous bloom pump with mixed-flow output
US4863461A (en) * 1988-03-21 1989-09-05 Symbion, Inc. Artificial ventricle
US4846831A (en) * 1988-04-27 1989-07-11 Skillin David E Manual back-up drive for artificial heart
US4906229A (en) * 1988-05-03 1990-03-06 Nimbus Medical, Inc. High-frequency transvalvular axisymmetric blood pump
US4888011A (en) * 1988-07-07 1989-12-19 Abiomed, Inc. Artificial heart
US4919647A (en) * 1988-10-13 1990-04-24 Kensey Nash Corporation Aortically located blood pumping catheter and method of use
US4902291A (en) * 1989-01-31 1990-02-20 University Of Utah Research Foundation Collapsible artificial ventricle and pumping shell
US5089019A (en) * 1989-12-06 1992-02-18 Medtronic, Inc. Muscle work output monitor by intramuscular temperature variation measurement
US5098442A (en) * 1989-12-06 1992-03-24 Medtronic, Inc. Muscle contraction control by intramuscular pressure monitoring
US5067960A (en) * 1989-12-06 1991-11-26 Medtronic, Inc. Muscle fitness detection by colorimetry
US5358519A (en) * 1989-12-06 1994-10-25 Medtronic, Inc. Muscle control and monitoring system
US5069680A (en) * 1989-12-06 1991-12-03 Medtronic, Inc. Muscle stimulator with variable duty cycle
US5131905A (en) * 1990-07-16 1992-07-21 Grooters Ronald K External cardiac assist device
US5205810A (en) * 1990-10-15 1993-04-27 Medtronic, Inc. Muscle powered cardiac assist system
WO1992008500A1 (en) * 1990-11-09 1992-05-29 Mcgill University Cardiac assist method and apparatus
US5119804A (en) * 1990-11-19 1992-06-09 Anstadt George L Heart massage apparatus
US5425364A (en) * 1991-02-15 1995-06-20 Cardiac Pathways Corporation Flexible strip assembly without feedthrough holes and device utilizing the same
US5156151A (en) * 1991-02-15 1992-10-20 Cardiac Pathways Corporation Endocardial mapping and ablation system and catheter probe
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5411025A (en) * 1992-06-30 1995-05-02 Cordis Webster, Inc. Cardiovascular catheter with laterally stable basket-shaped electrode array
US5383840A (en) * 1992-07-28 1995-01-24 Vascor, Inc. Biocompatible ventricular assist and arrhythmia control device including cardiac compression band-stay-pad assembly
US5290227A (en) * 1992-08-06 1994-03-01 Pasque Michael K Method of implanting blood pump in ascending aorta or main pulmonary artery
US5332403A (en) * 1992-08-17 1994-07-26 Jack Kolff LVAD with t-shape and unidirectional valve
US5447533A (en) * 1992-09-03 1995-09-05 Pacesetter, Inc. Implantable stimulation lead having an advanceable therapeutic drug delivery system
US5326374A (en) * 1992-12-01 1994-07-05 Michael N. Ilbawi Body-implantable device for controlling the size of a fluid passageway
ES2077519B1 (en) * 1993-11-22 1996-07-01 Fernandez De Lomana Euge Anaya INTRAAORTIC CATHETER FOR RENAL PERFUSION AND CONSERVATION.
US5598848A (en) * 1994-03-31 1997-02-04 Ep Technologies, Inc. Systems and methods for positioning multiple electrode structures in electrical contact with the myocardium
US5484385A (en) * 1994-04-21 1996-01-16 C. R. Bard, Inc. Intra-aortic balloon catheter
US5800528A (en) * 1995-06-13 1998-09-01 Abiomed R & D, Inc. Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation
US5824028A (en) * 1996-09-20 1998-10-20 The Uab Research Foundation Line electrode oriented relative to fiber direction
US5702343A (en) * 1996-10-02 1997-12-30 Acorn Medical, Inc. Cardiac reinforcement device
WO1998017347A1 (en) * 1996-10-18 1998-04-30 Cardio Technologies, Inc. Method and apparatus for assisting a heart
US5961440A (en) * 1997-01-02 1999-10-05 Myocor, Inc. Heart wall tension reduction apparatus and method
US6190408B1 (en) * 1998-03-05 2001-02-20 The University Of Cincinnati Device and method for restructuring the heart chamber geometry
US6110100A (en) * 1998-04-22 2000-08-29 Scimed Life Systems, Inc. System for stress relieving the heart muscle and for controlling heart function

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3827426A (en) * 1971-07-16 1974-08-06 P Sawyer Prosthetic pump
US3983863A (en) * 1975-06-02 1976-10-05 American Hospital Supply Corporation Heart support for coronary artery surgery
EP0303719A1 (en) * 1987-02-23 1989-02-22 Blagoveschensky Gosudarstvenny Meditsinsky Institut Artificial pericardium
WO1997024101A1 (en) * 1996-01-02 1997-07-10 David Boyd Melvin Activation device for the natural heart and method of doing the same
WO1998029041A1 (en) * 1997-01-02 1998-07-09 Myocor, Inc. Heart wall tension reduction apparatus and method
WO1998055165A1 (en) * 1997-06-06 1998-12-10 Woodard John C Cardiac assist device
WO1998058598A1 (en) * 1997-06-21 1998-12-30 Hans Haindl Bag for at least partially enveloping a heart

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221103B1 (en) 1996-01-02 2001-04-24 The University Of Cincinnati Device and method for restructuring heart chamber geometry
US7361191B2 (en) 1996-01-02 2008-04-22 The University Of Cincinnati Heart wall actuation device for the natural heart
US6520904B1 (en) 1996-01-02 2003-02-18 The University Of Cincinnati Device and method for restructuring heart chamber geometry
US6592619B2 (en) 1996-01-02 2003-07-15 University Of Cincinnati Heart wall actuation device for the natural heart
US8226711B2 (en) 1997-12-17 2012-07-24 Edwards Lifesciences, Llc Valve to myocardium tension members device and method
US6190408B1 (en) 1998-03-05 2001-02-20 The University Of Cincinnati Device and method for restructuring the heart chamber geometry
US6409760B1 (en) 1998-03-05 2002-06-25 University Of Cincinnati Device and method for restructuring heart chamber geometry
US7981020B2 (en) 1998-07-29 2011-07-19 Edwards Lifesciences Llc Transventricular implant tools and devices
US7722523B2 (en) 1998-07-29 2010-05-25 Edwards Lifesciences Llc Transventricular implant tools and devices
US8579798B2 (en) 1998-09-21 2013-11-12 Edwards Lifesciences, Llc External cardiac stress reduction method
US7044967B1 (en) 1999-06-29 2006-05-16 Edwards Lifesciences Ag Device and method for treatment of mitral insufficiency
US6997951B2 (en) 1999-06-30 2006-02-14 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
US7090695B2 (en) 1999-06-30 2006-08-15 Edwards Lifesciences Ag Method for treatment of mitral insufficiency
US7192442B2 (en) 1999-06-30 2007-03-20 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
EP1629794A3 (en) * 2000-01-31 2009-07-01 Edwards Lifesciences AG Percutaneous mitral annuloplasty and cardiac reinforcement
WO2001067985A1 (en) * 2000-03-10 2001-09-20 Paracor Surgical, Inc. Expandable cardiac harness for treating congestive heart failure
US7766812B2 (en) 2000-10-06 2010-08-03 Edwards Lifesciences Llc Methods and devices for improving mitral valve function
US9198757B2 (en) 2000-10-06 2015-12-01 Edwards Lifesciences, Llc Methods and devices for improving mitral valve function
EP2520229A3 (en) * 2001-07-16 2013-03-20 Corassist Cardiovascular Ltd. In-vivo method and device for improving diastolic function of the left ventricle
US7993258B2 (en) 2001-07-16 2011-08-09 Corassist Cardiovascular Ltd. In-vivo method and device for improving diastolic function of the left ventricle
US8092367B2 (en) 2001-09-07 2012-01-10 Mardil, Inc. Method for external stabilization of the base of the heart
US8128553B2 (en) 2001-09-07 2012-03-06 Mardil, Inc. Method and apparatus for external stabilization of the heart
US9289298B2 (en) 2001-09-07 2016-03-22 Mardil, Inc. Method and apparatus for external stabilization of the heart
US7678145B2 (en) 2002-01-09 2010-03-16 Edwards Lifesciences Llc Devices and methods for heart valve treatment
US8070805B2 (en) 2002-01-09 2011-12-06 Edwards Lifesciences Llc Devices and methods for heart valve treatment
JP2005523049A (en) * 2002-01-31 2005-08-04 シメッド ライフ システムズ インコーポレイテッド Medical device for releasing biologically active substances
US7081084B2 (en) 2002-07-16 2006-07-25 University Of Cincinnati Modular power system and method for a heart wall actuation system for the natural heart
US7666224B2 (en) 2002-11-12 2010-02-23 Edwards Lifesciences Llc Devices and methods for heart valve treatment
EP1594569A4 (en) * 2003-01-27 2010-01-06 Corassist Cardiovascular Ltd In vivo device for improving diastolic ventricular function
EP1594569A2 (en) * 2003-01-27 2005-11-16 Corassist Cardiovascular Ltd. In vivo device for improving diastolic ventricular function
WO2008144696A1 (en) 2007-05-21 2008-11-27 Bioventrix (Aka Chf Technologies, Inc.) Methods and implants for treatment of cardiac failure
EP2150312A4 (en) * 2007-05-21 2015-03-11 Bioventrix Aka Chf Technologies Inc Methods and implants for treatment of cardiac failure

Also Published As

Publication number Publication date
JP4190730B2 (en) 2008-12-03
US6494825B1 (en) 2002-12-17
JP2002512091A (en) 2002-04-23
EP1073488A1 (en) 2001-02-07
CA2329735A1 (en) 1999-10-28
US6110100A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
US6110100A (en) System for stress relieving the heart muscle and for controlling heart function
US7499749B2 (en) Method and apparatus for minimizing post-infarct ventricular remodeling
US8121684B2 (en) Method and apparatus for minimizing post-infarct ventricular remodeling
US6169922B1 (en) Defibrillating cardiac jacket with interwoven electrode grids
US6564094B2 (en) Cardiac disease treatment and device
US7440800B2 (en) System and method for managing detrimental cardiac remodeling
US20040010180A1 (en) Cardiac assist system
US7935045B2 (en) Device for proactive modulation of cardiac strain patterns
US9295845B2 (en) Post-MI pacing with autocapture function
JP5366056B2 (en) Myocardial ischemia treatment device
CA2652372A1 (en) Cardiac harness having diagnostic sensors and method of use
US8406878B2 (en) Method for treating myocardial infarction
EP1377209A1 (en) Cardiac stabilizers
US8447399B2 (en) System and method for managing detrimental cardiac remodeling
US10220128B1 (en) Implanted cardiac device to treat heart failure
KR20070062455A (en) A system and method for managing detrimental cardiac remodeling
JP4190730B6 (en) A system to control cardiac function by relieving myocardial stress

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2329735

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999917645

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 544377

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999917645

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999917645

Country of ref document: EP